https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Biotinylated Anti-Cetuximab Antibodies (AY31) (recommended for PK/PD)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Cetuximab Antibodies (AY27) (recommended for ADA assay)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Cetuximab Antibodies (AY27) (recommended for ADA assay)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Cetuximab Antibodies (AY28)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Cetuximab Antibodies (AY28)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Cetuximab Antibodies (AY29) (recommended for PK/PD)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Cetuximab Antibodies (AY31) (Non-Neutralizing)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Cetuximab Antibodies (AY31) (Non-Neutralizing)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Adalimumab Antibodies (AY19)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Adalimumab Antibodies (AY19)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Bevacizumab Antibodies (AY10) (MALS verified, recommended for PK/PD)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Bevacizumab Antibodies (AY12) (recommended for neutralizing assay)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Bevacizumab Antibodies (AY12) (recommended for neutralizing assay)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Bevacizumab Antibodies (AY9) (recommended for ADA assay)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Anti-Bevacizumab Antibodies (AY9) (recommended for ADA assay)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:44:15 2023-02-21 12:44:15 Biotinylated Anti-Cetuximab Antibodies (AY31) (recommended for PK/PD)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:43:59 2023-02-21 12:43:59 APC-Labeled Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 (Y45) (Site-specific conjugation)
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
0
0
sophie@kahuna.co.il
https://doronscientific.com/wp-content/uploads/2022/12/doron-scintific-logo.png
sophie@kahuna.co.il 2023-02-21 12:43:59 2023-02-21 12:43:59 APC-Labeled Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 (Y45) (Site-specific conjugation)
Scroll to top
Skip to content